All In Biotech

Drug Trial Radar · NCT06041646

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

29

Actual

Start

Oct 2, 2023

Primary completion

Apr 29, 2024

Study completion Apr 29, 2024

Sponsor

Lead sponsor
BioXcel Therapeutics IncIndustry
Sponsor type
Industry
Collaborators
Lotus Clinical Research, LLC
First posted
Sep 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.

Conditions

  • Bipolar Disorder
  • Schizophrenia
  • Agitation,Psychomotor
  • Schizo Affective Disorder
  • Schizophreniform Disorders

Interventions

  • Sublingual film containing IgalmiDrug

    Sublingual film containing 180 µg of Igalmi (dexmedetomidine)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total ScoreTime frame: Baseline and 2 hours post-dose for all doses administered over 7 days.
  2. Clinical Global Impression - Improvement (CGI-I)Time frame: 2 hours post-dose for all doses administered over 7 days.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • BioXcel Clinical Research Site

    Little Rock, Arkansas

  • BioXcel Clinical Research Site

    Rogers, Arkansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.